Quantitative Synthetic Biology to Advance Viral Vector Production

Tuesday, March 19, 2024 at 4:30 PM to 4:50 PM · 20 min. (Europe/London)
Viral Vector Manufacturing [Track 9]
Presentation
Asimov
98
Asimov is developing a synthetic biology platform – from cells to software – to design and manufacture next-generation therapeutics, including biologics, cell/gene therapies, and RNA through a combination of products, services, and collaborations. At Advanced Therapies Congress, we’ll be presenting our LV Edge System for lentivirus production, which integrates stable cell lines and software design tools to routinely achieve lentiviral titers over 1E8 TU/mL for therapeutic transgenes. Founded by bioengineers from MIT and Boston University and headquartered in Boston, the company has raised over $200 million from top institutional investors including Andreessen Horowitz, CPP Investments, Horizons Ventures, and Fidelity Management & Research Company. For more information, visit www.asimov.com

Documents & Links

  • Quantitative Synthetic Biology to Advance Viral Vector Production

Registered attendees

Emmanuelle Cameau
Emmanuelle Cameau
Scientific Director Viral VectorsCytiva
Holger Laux
Holger Laux
Director of Genetic MedicineCSL Behring
imen mestiri
imen mestiri
Business Development LeadGenethon

Log in

See all the content and easy-to-use features by logging in or registering!